دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Perinatal depression: a neglected aspect of maternal health
doi : 10.1016/S0140-6736(23)01786-5
Volume 402, Issue 10403, 26 August–1 September 2023, Page 667
The pursuit of optimal semaglutide dosing in type 2 diabetes continues
*Christina H Sherrill, Andrew Y Hwang
doi : 10.1016/S0140-6736(23)01233-3
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 668-669
Oral semaglutide: an OASIS from injectables
*Priya Manjoo, Arya M Sharma
doi : 10.1016/S0140-6736(23)01479-4
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 670-671
CagriSema and the link between obesity and type 2 diabetes
*Caroline M Apovian, Marie E McDonnell
doi : 10.1016/S0140-6736(23)01291-6
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 671-673
Improving health system performance in Mexico
Karla Unger-Salda?a, Mart?n Lajous, Michael R Reich
doi : 10.1016/S0140-6736(23)01454-X
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 674-676
Strengthening Africa's voice on boards of global health initiatives
Magda Robalo Correia e Silva, Pokuaa Oduro-Bonsrah, Purity Wambui, Mohamed Chakroun
doi : 10.1016/S0140-6736(23)01574-X
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 677-678
Syria after the earthquake
Daniel Skyle
doi : 10.1016/S0140-6736(23)01784-1
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 679-680
China's crackdown on health-care corruption
Shawn Yuan
doi : 10.1016/S0140-6736(23)01785-3
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 681-682
Chinyere Ezeaka: reforming newborn health care in Nigeria
Rachael Davies
doi : 10.1016/S0140-6736(23)01738-5
Volume 402, Issue 10403, 26 August–1 September 2023, Page 683
What do you see when you look at me? Narratives of visible disease
Roopa Farooki
doi : 10.1016/S0140-6736(23)01739-7
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 684-685
William Sidney Robinson
Geoff Watts
doi : 10.1016/S0140-6736(23)01740-3
Volume 402, Issue 10403, 26 August–1 September 2023, Page 686
Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection
Lianpan Dai, Huixin Duan, Xueyuan Liu, Huan Zhou, Minrun Duan, Yaling An, Linfeng Yuan, Xin Zhao, Kun Xu, Qiang Wu, *George F Gao
doi : 10.1016/S0140-6736(23)01367-3
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 687-689
Israel's judicial overhaul: a threat to the Health in All Policies approach
Shelly Kamin-Friedman, Hagai Levine, Nadav Davidovitch, Aron M Troen, *Y Tony Yang
doi : 10.1016/S0140-6736(23)01663-X
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 689-690
Concerns about new proposals for haemochromatosis screening
Neil McClements
doi : 10.1016/S0140-6736(23)01506-4
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 690-691
Concerns about new proposals for haemochromatosis screening
Louise Fish
doi : 10.1016/S0140-6736(23)01507-6
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 691-692
Concerns about new proposals for haemochromatosis screening – Authors' reply
Paul C Adams, Gary P Jeffrey, John Ryan
doi : 10.1016/S0140-6736(23)01504-0
Volume 402, Issue 10403, 26 August–1 September 2023, Page 692
Department of Error
doi : 10.1016/S0140-6736(23)01743-9
Volume 402, Issue 10403, 26 August–1 September 2023, Page 692
Department of Error
doi : 10.1016/S0140-6736(23)01742-7
Volume 402, Issue 10403, 26 August–1 September 2023, Page 692
Department of Error
doi : 10.1016/S0140-6736(23)01741-5
Volume 402, Issue 10403, 26 August–1 September 2023, Page 692
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
Vanita R Aroda, Jens Aberle, Lars Bardtrum, Erik Christiansen, Filip K Knop, Sanaz Gabery, Sue D Pedersen, John B Buse
doi : 10.1016/S0140-6736(23)01127-3
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 693-704
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K Knop, Vanita R Aroda, Ruben D do Vale, Thomas Holst-Hansen, Peter N Laursen, Julio Rosenstock, Domenica M Rubino, W Timothy Garvey, for the OASIS 1 Investigators
doi : 10.1016/S0140-6736(23)01185-6
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 705-719
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P Frias, Srikanth Deenadayalan, Lars Erichsen, Filip K Knop, Ildiko Lingvay, Stanislava Macura, Chantal Mathieu, Sue D Pedersen, Melanie Davies
doi : 10.1016/S0140-6736(23)01163-7
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 720-730
Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia
Sheraz Yaqub, Ida Bj?rk, Meryam Sugulle, Trine Folseraas
doi : 10.1016/S0140-6736(23)01606-9
Volume 402, Issue 10403, 26 August–1 September 2023, Page e10
Setbacks in the quest for universal health coverage in Mexico: polarised politics, policy upheaval, and pandemic disruption
Felicia Marie Knaul, Hector Arreola-Ornelas, Michael Touchton, Tim McDonald , Merike Blofield, Leticia Avila Burgos, Octavio G?mez-Dantés, Pablo Kuri, Adolfo Martinez-Valle, Oscar Méndez-Carniado, Renu Sara Nargund, Thalia Porteny, Sandra Gabriela Sosa-Rub?, Edson Serv?n-Mori, Maya Symes, Valentina Vargas Enciso, Julio Frenk
doi : 10.1016/S0140-6736(23)00777-8
Volume 402, Issue 10403, 26 August–1 September 2023, Pages 731-746
